Loading...
Loading...
RXDX| Name | Value |
|---|---|
| Revenues | 1.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 1.0M |
| Operating Expense | 39.4M |
| Operating I/L | -38.4M |
| Other Income/Expense | 1.1M |
| Interest Income | 1.1M |
| Pretax | -37.3M |
| Income Tax Expense | -1.1M |
| Net Income/Loss | -36.2M |
Prometheus Biosciences, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). The company's lead product, PRA023, is a humanized IgG1 monoclonal antibody (mAb) currently in Phase IIa clinical trial for the treatment of ulcerative colitis, Crohn's disease, and systemic sclerosis-associated interstitial lung disease. Additionally, the company is developing a range of other products including anti-tumor necrosis factor mAb, G-protein coupled receptor modulator small molecule, anti-cytokine receptor mAb, anti-chemokine mAb, and anti-inflammatory cytokine mAb for IBD and other immune-mediated diseases.
